Tumor Primary Site and Histology Subtypes Role in Radiotherapeutic Management of Brain Metastases
Randomized controlled trials have failed to report any survival advantage for WBRT combined with SRS in the management of brain metastases, despite the enhanced local and distant control in comparison to each treatment alone. Literature review have revealed important role of primary histology of the tumor when dealing with brain metastases. NSCLC responds better to combined approach even when there was only single brain metastasis present while breast cancer has registered better survival with SRS alone probably due to better response of primary tumor to advancement in surgical and chemotherapeutic agents. Furthermore, mutation status (EGFR/ALK) in lung cancer and receptor status (ER/PR/HER2) in breast cancer also exhibit diversity in their response to radiotherapy. Radioresistant tumors like renal cell carcinoma and melanoma brain metastases have achieved better results when treated with SRS alone. Secondly, single brain metastasis may benefit from local and distant brain control achieved with combined treatment. These diverse outcomes suggest a primary histology-based analysis of the radiotherapy regimens (WBRT, SRS, or their combination) would more ideally establish the role of radiotherapy in the management of brain metastases. Molecularly targeted therapeutic and immunotherapeutic agents have revealed synergism with radiation therapy particularly SRS in treating cancer patients with brain metastases. Clinical updates in this regard have also been reviewed.
In this study, microarray analysis was used for gene expression profiling in rat prostate tissue after exposure to EDCs and sex hormones over multiple time points (prepubertal through adulthood). We used dorsolateral prostate tissues from Sprague-Dawley rats (male offspring) and postnatally administered estradiol benzoate (EB) on postnatal days (PNDs) 1, 3, and 5, followed by treatment with additional hormones [estradiol (E) and testosterone (T)] on PNDs 90-200, as described by Ho et al. Microarray analysis was performed for gene expression profiling in the dorsolateral prostate, and the results were validated via qRT-PCR....
CONCLUSIONS: Type 1 diabetes in both genders and all ages was associated with significantly elevated SMRs for all-cause and mostly for diabetes per se and renal disease. PMID: 32741854 [PubMed - as supplied by publisher]
Do you guys think there is enough volume to support an outpatient interventional cancer pain &cancer rehab practice? I will be starting my PM&R residency training at one of the top programs in the country after this academic year (am an prelim medicine intern right now). And I ultimately want to help cancer survivors. I think with the continuing improvements with cancer treatments (most recently with immunotherapy), cancer will be/is a chronic disease with debilitating side effects that... cancer pain only practice
Publication date: Available online 4 August 2020Source: Academic RadiologyAuthor(s): Eric S. Fair, Petar Duvnjak
Publication date: Available online 4 August 2020Source: Pathology - Research and PracticeAuthor(s): Guocheng Huang, Huijuan Li, Jingyao Wang, Xiqi Peng, Kaihao Liu, Liwen Zhao, Chunduo Zhang, Xuan Chen, Yongqing Lai, Liangchao Ni
Publication date: Available online 4 August 2020Source: Pathology - Research and PracticeAuthor(s): Chenghao Lu, Zheyu Yang, Dingye Yu, Jianwei Lin, Wei Cai
Even though New York Oncology Hematology is working to help patients understand that medical offices are safe, the practice has seen a drop in the number of people getting regular cancer screenings. And that could have negative impacts on long-term care and the economy.
We describe the role of dosimetry in redifferentiation and subsequent I-131 therapy in RAI-R thyroid cancer, explain different dosimetry approaches and discuss limitations and considerations in the field. PMID: 32744039 [PubMed - in process]
Publication date: Available online 3 August 2020Source: Gynecologic Oncology ReportsAuthor(s): Tyler J. Woodard, Benjamin Margolis, Sarah Lee, Ghadir Salame
Publication date: Available online 3 August 2020Source: Gynecologic Oncology ReportsAuthor(s): Kevin M. Kremer, Jessica Lee, Matthew J. Carlson, Salvatore J. Lococo, David S. Miller, Jayanthi S. Lea